* dopamine receptor antagonists
** receptor
D2
** low potency agents
*** [#B] ideal receptor occupancy
60-70%
** high potency agents
* side effects of typical anti-psychotics
** [#A] akathisia
- motor restlessness; /not anxiety or agitation/
- treatment---reduce dose or change drug; antiparkinsonian agents, propranolol, or benzodiazepines may help
* prediction of therapeutic dosing
- D2 antagonism
- the basis of the therapeutic benefit of antipsychotics is blocking D2
- preferential binding to D2---D2:D1 = 5:1 receptor occupancy
* schizophrenia
** pathophysiology
*** [#B] mesocortical
- hypoactive / hypofunctional
- negative symptoms
*** [#B] mesolimbic
- hyperactive / hyperfunctional
- positive symptoms
** drug classes
*** first generation antipsycotics
*** second generation antipsychotics
**** Abilify
***** brand
aripiprazole
***** black box warning
agranulocytosis
**** Saphris
***** brand
asenapine
**** Clozaril
***** brand
clozapine
***** [#A] monitoring
ANC...
- general population ≥ 1500 μL
- benign ethnic neutropenia ≥ 1000 μL
**** Fanapt
***** brand
iloperidone
**** Latuda
***** brand
lurasidone
**** Rexulti
***** brand
brexpiprazole
**** Zyprexa
***** brand
olanzapine
**** Seroquel
***** brand
quetiapine
***** [#B] adverse effects
- weight gain / metabolic syndrome
- sedation
***** monitoring
- increases LFTs
- requires hepatic dose adjustments
**** Invega
***** brand
paliperidone
***** counseling
tablet shell may appear in stool
***** [#B] pharmacology
active metabolite of risperidone; therefore, failure of risperidone may indicate failure of paliperidone
**** Risperdal
***** brand
risperidone
**** Geodon
***** [#B] therapeutic use
- *greatest risk of QT prolongation*
- weight neutral
- must use with 500 calories
***** brand
ziprasidone
**** Vraylar
***** brand
cariprazine
*** injectable antipsychotics
**** aripiprazole
***** brand :l:
****** Abilify Maintena
****** Aristada
prodrug of aripiprazole
**** risperidone
**** olanzapine
***** brand
Zyprexa Relprevv
**** paliperidone palmitate
***** brand
- Invega Sustenna
- Invega Trinza
***** usage notes
sustain 4 months of Invega Sustenna before starting Invega Trinza
** therapeutics
*** acute
**** [#B] do not combine
IM Lorazepam + Olanzapine
*** movement disorders
**** dystonia
- anticholinergics…
  - diphenydramine
  - benztropine (Cogentin)
- lower the dose of antipsychotic or switch to another agent
**** [#A] akathisia
- β-blockers
- benzodiazepines
- propranolol
- *do not use anticholinergics*
**** pseudoparkinsonism
- anticholinergic agents …
  - diphenydramine
  - benztropine (Cogentin)
  - trihexyphenidyl (Artane)
- amantadine---an antiviral, not an anticholinergic, but also increases dopamine
**** tardive dyskinesia
***** clinical presentation
- stereotypical involuntary movements; twitches
- latent onset after starting a drug
*** highest risk for metabolic syndrome
- clozapine
- olanzapine
- quetiapine
* delirium
** treatment
- antipsychotics
  - haloperidol
  - second generation antipsychotics
- benzodiazepines
- *do not use cholinesterase inhibitors*
* neuroleptic malignant syndrome
** [#A] symptoms
- high fever
- confusion
- rigidity
** [#A] treatment
dantrolene
* bipolar
** lithium
*** [#A] mechanism of action
depletion of intracellular inositol
*** [#A] therapeutic range
0.6-1.5 mEq/L
*** pharmacodynamics
- ↓ Na
*** pharmacokinetics
**** interactions
- caffeine
- diuretics
- NSAIDs
- ACE/ARBs
**** [#A] monitoring
obtain trough 10-12 hours after administration
*** TODO signs and symptoms (?)
*** [#A] contraindications
- pregnancy category D---do not use in the 1st trimester
- renal impairment
- severe thyroid disorders
- cardiac disorders
** divalproex sodium aka valproic acid
*** brand
Depakote
*** pharmacokinetics
**** metabolism
divalproex sodium metabolizes to valproic acid
*** [#A] serum concentration
50-100 mcg/mL
*** contraindications
pregnancy category D---do not use in the 1st trimester
** carbamazepine
*** [#B] pharmacokinetics
- autoinducer---induces own metabolism
- CYP3A4 inducer
*** contraindications
pregnancy category D---do not use in the 1st trimester
** lamotrigine
*** [#A] adverse drug reactions
- Steven Johnson’s Syndrome
- rash; most likely develops in first month of therapy
*** dose
- 25 mg daily for 2 weeks
- increase until maintenance at 400 mg/day
- /titrate/ up
** therapeutics
*** manic or mixed episode
- lithium
- divalproex sodium
- antipsychotic
*** depressive episode
- lithium
- lamotrigine
- for severe cases: antidepressants
*** special cases
**** [#A] manic patient on antidepressants
discontinue the antidepressants because they overstimulate neurotransmitters already elevated
